Ensign Peak Advisors Inc Buys 152,685 Shares of Gilead Sciences, Inc. $GILD

Ensign Peak Advisors Inc lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,297,702 shares of the biopharmaceutical company’s stock after acquiring an additional 152,685 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.19% of Gilead Sciences worth $254,746,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. Rothschild Investment LLC boosted its position in Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 84 shares during the last quarter. EPG Wealth Management LLC increased its holdings in Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 89 shares during the last quarter. Southland Equity Partners LLC raised its position in Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 92 shares during the period. Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the period. Finally, Twelve Points Wealth Management LLC raised its holdings in shares of Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 98 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $128.07 on Thursday. The stock has a market cap of $158.89 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 0.81 and a beta of 0.32. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business has a 50-day simple moving average of $118.09 and a 200 day simple moving average of $113.29. Gilead Sciences, Inc. has a 52 week low of $87.77 and a 52 week high of $128.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the company posted $2.02 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. The trade was a 1.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 125,146 shares of company stock worth $15,148,441. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. BMO Capital Markets upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Finally, Truist Financial reiterated a “buy” rating and issued a $145.00 price objective (up from $127.00) on shares of Gilead Sciences in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.13.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.